Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Bladder cancer
Checkpoint Inhibitor
Immunotherapy
Outcomes
Platinum resistance
Journal
Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
29
07
2022
accepted:
15
08
2022
pubmed:
27
9
2022
medline:
6
12
2022
entrez:
26
9
2022
Statut:
ppublish
Résumé
Early progression on first-line (1L) platinum-based therapy or between therapy lines may be a surrogate of more aggressive disease and poor outcomes in advanced urothelial carcinoma (aUC), but its prognostic role regarding immune checkpoint inhibitor (ICI) response and survival is unclear. We hypothesized that shorter time until start of second-line (2L) ICI would be associated with worse outcomes in aUC. We performed a retrospective multi-institution cohort study in patients with aUC treated with 1L platinum-based chemotherapy, who received 2L ICI. Patients receiving switch maintenance ICI were excluded. We defined time to 2L ICI therapy as the time between the start of 1L platinum-based chemotherapy to the start of 2L ICI and categorized patients a priori into 1 of 3 groups: less than 3 months versus 3-6 months versus more than 6 months. We calculated overall response rate (ORR) with 2L ICI, progression-free survival (PFS) and overall survival (OS) from the start of 2L ICI. ORR was compared among the 3 groups using multivariable logistic regression, and PFS, OS using cox regression. Multivariable models were adjusted for known prognostic factors. We included 215, 215, and 219 patients in the ORR, PFS, and OS analyses, respectively, after exclusions. ORR difference did not reach statistical significance between patients with less than 3 months versus 3-6 months versus more than 6 months to 2L ICI. However, PFS (HR 1.64; 95% CI 1.02-2.63) and OS (HR 1.77; 95% CI 1.10-2.84) was shorter among those with time to 2L ICI less than 3 months compared to those who initiated 2L ICI more than 6 months. Among patients with aUC treated with 2L ICI, time to 2L ICI less than 3 months was associated with lower, but not significantly different ORR, but shorter PFS and OS compared to 2L ICI more than 6 months. This highlights potential cross resistance mechanisms between ICI and platinum-based chemotherapy.
Sections du résumé
BACKGROUND
Early progression on first-line (1L) platinum-based therapy or between therapy lines may be a surrogate of more aggressive disease and poor outcomes in advanced urothelial carcinoma (aUC), but its prognostic role regarding immune checkpoint inhibitor (ICI) response and survival is unclear. We hypothesized that shorter time until start of second-line (2L) ICI would be associated with worse outcomes in aUC.
PATIENTS AND METHODS
We performed a retrospective multi-institution cohort study in patients with aUC treated with 1L platinum-based chemotherapy, who received 2L ICI. Patients receiving switch maintenance ICI were excluded. We defined time to 2L ICI therapy as the time between the start of 1L platinum-based chemotherapy to the start of 2L ICI and categorized patients a priori into 1 of 3 groups: less than 3 months versus 3-6 months versus more than 6 months. We calculated overall response rate (ORR) with 2L ICI, progression-free survival (PFS) and overall survival (OS) from the start of 2L ICI. ORR was compared among the 3 groups using multivariable logistic regression, and PFS, OS using cox regression. Multivariable models were adjusted for known prognostic factors.
RESULTS
We included 215, 215, and 219 patients in the ORR, PFS, and OS analyses, respectively, after exclusions. ORR difference did not reach statistical significance between patients with less than 3 months versus 3-6 months versus more than 6 months to 2L ICI. However, PFS (HR 1.64; 95% CI 1.02-2.63) and OS (HR 1.77; 95% CI 1.10-2.84) was shorter among those with time to 2L ICI less than 3 months compared to those who initiated 2L ICI more than 6 months.
CONCLUSION
Among patients with aUC treated with 2L ICI, time to 2L ICI less than 3 months was associated with lower, but not significantly different ORR, but shorter PFS and OS compared to 2L ICI more than 6 months. This highlights potential cross resistance mechanisms between ICI and platinum-based chemotherapy.
Identifiants
pubmed: 36155169
pii: S1558-7673(22)00174-4
doi: 10.1016/j.clgc.2022.08.006
pmc: PMC10233855
mid: NIHMS1900255
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
558-567Subventions
Organisme : NCI NIH HHS
ID : P30 CA023100
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA094880
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
Int J Cancer. 1999 Dec 10;83(6):848-51
pubmed: 10597209
Nat Med. 2021 May;27(5):793-801
pubmed: 33941921
J Urol. 2020 Dec;204(6):1173-1179
pubmed: 32552295
Expert Opin Investig Drugs. 2010 Nov;19(11):1339-54
pubmed: 20815774
J Clin Oncol. 2018 Jun 10;36(17):1685-1694
pubmed: 29489427
Cancer Immunol Res. 2016 Jul;4(7):563-8
pubmed: 27197067
Eur Urol Oncol. 2021 Jun;4(3):464-472
pubmed: 33423945
Clin Cancer Res. 2008 Mar 1;14(5):1291-5
pubmed: 18316546
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Cancer Res. 2020 Oct 1;26(19):5120-5128
pubmed: 32532789
J Clin Oncol. 2010 Apr 10;28(11):1850-5
pubmed: 20231682
Lancet Oncol. 2018 Jan;19(1):51-64
pubmed: 29217288
Semin Cancer Biol. 2021 Dec;77:127-143
pubmed: 32931951
Cancer. 2019 Feb 15;125(4):533-540
pubmed: 30570744
Cancer. 2020 Mar 15;126(6):1208-1216
pubmed: 31829450
Clin Cancer Res. 2017 Jul 15;23(14):3610-3618
pubmed: 28137924
N Engl J Med. 2020 Sep 24;383(13):1218-1230
pubmed: 32945632
Eur Urol. 2013 Apr;63(4):717-23
pubmed: 23206856
BMC Cancer. 2021 May 24;21(1):593
pubmed: 34030643
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
J Clin Oncol. 2000 Sep;18(17):3068-77
pubmed: 11001674
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060